The value of serum prostate specific antigen and other parameters in detecting bone metastases in prostate cancer

被引：12

作者：

Ataus S. ^{[1
]}

Çitçi A. ^{[1
]}

Alici B. ^{[1
]}

Önder A.U. ^{[1
]}

Sönmezoǧlu K. ^{[2
]}

Erözenci A. ^{[1
]}

Solok V. ^{[1
]}

机构：

[1] Department of Urology, Cerrahpasa School of Medicine, Istanbul University, Istanbul

[2] Department of Nuclear Medicine, Cerrahpasa School of Medicine, Istanbul University, Istanbul

来源：

International Urology and Nephrology | 1999年 / 31卷 / 4期

关键词：

Public Health; Prostate Cancer; Bone Metastasis; Clinical Stage; Prostate Specific Antigen;

D O I：

10.1023/A:1007163227968

中图分类号：

学科分类号：

摘要：

The cut-off value of serum prostate-specific antigen (PSA) level in prediction of bone metastases and the correlation of serum PSA with the clinical stage, grade, score and the rate of bone metastases have been investigated in cases of prostate cancer (PCa). The study population consisted of 160 patients with histologically proven PCa between April, 1993 and August, 1996. The negative predictive value and the sensitivity were the highest (94%) in patients with a serum PSA value less than 10 ng/ml. We claim that in patients with PSA values less than 10 ng/ml whole body bone scan is not necessary.

引用

页码：481 / 489

页数：8

共 26 条

[1] Parker S.L., Tong T., Bolden S., Wingo P.A., Cancer statistics, 1996, CA, 46, (1996)
[2] Oesterling J.E., Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate, J. Urol., 145, (1991)
[3] Benson C.M., Olsson C.A., Prostate specific antigen and prostate specific antigen density, Cancer, 6-74, (1994)
[4] Ernst D.S., Hanson J., Venner P.M., Uro-Oncology group of Northern Alberta: Analysis of prognostic factors in men with metastatic prostate cancer, J. Urol., 146, (1991)
[5] Cheryl T.L., Oesterling J.E., Using prostate-specific antigen to eliminate the staging radionuclide bone scan, Urol. Clin. North Amer., 24, 2, (1997)
[6] Jacobs S.C., Spread of prostatic cancer to bone, Urology, 21, (1983)
[7] Paulson D.F., The impact of current staging procedures in assessing the disease extent of prostatic adenocarcinoma, J Urol., 121, (1979)
[8] McGregor B., Tulloch A.G.S., Quinlan M.F., Lovegrove F., The role of bone scanning in the assessment of prostatic carcinoma, Br. J. Urol., 50, (1978)
[9] Lentle B.C., McGowan D.G., Dierich H., Technetium 99M polyphosphate bone scanning in carcinoma of the prostate, Br. J. Urol., 46, (1974)
[10] Pollen J.J., Bone scanning in prostatic cancer, Urology, 17, (1981)

← 1 2 3 →